KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Opko Health (OPK) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Opko Health (OPK) over the last 16 years, with Q3 2025 value amounting to $415.2 million.

  • Opko Health's Cash & Equivalents rose 216.49% to $415.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $415.2 million, marking a year-over-year increase of 216.49%. This contributed to the annual value of $431.9 million for FY2024, which is 35049.18% up from last year.
  • Per Opko Health's latest filing, its Cash & Equivalents stood at $415.2 million for Q3 2025, which was up 216.49% from $271.7 million recorded in Q2 2025.
  • Over the past 5 years, Opko Health's Cash & Equivalents peaked at $436.0 million during Q1 2025, and registered a low of $40.6 million during Q2 2024.
  • Moreover, its 5-year median value for Cash & Equivalents was $138.6 million (2023), whereas its average is $190.3 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first soared by 83926.96% in 2021, then crashed by 6246.72% in 2024.
  • Quarter analysis of 5 years shows Opko Health's Cash & Equivalents stood at $134.7 million in 2021, then increased by 13.72% to $153.2 million in 2022, then tumbled by 37.41% to $95.9 million in 2023, then soared by 350.49% to $431.9 million in 2024, then dropped by 3.88% to $415.2 million in 2025.
  • Its Cash & Equivalents was $415.2 million in Q3 2025, compared to $271.7 million in Q2 2025 and $436.0 million in Q1 2025.